These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1561 related items for PubMed ID: 16900558

  • 1. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 2. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [Abstract] [Full Text] [Related]

  • 3. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C.
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [Abstract] [Full Text] [Related]

  • 4. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 6. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.
    Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C, Liu X.
    Oncogene; 2004 Jan 15; 23(2):457-64. PubMed ID: 14724574
    [Abstract] [Full Text] [Related]

  • 7. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 8. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C, Homicsko K, Lukashev AN, Pittet AL, Iggo RD.
    BMC Cancer; 2006 Oct 04; 6():236. PubMed ID: 17020613
    [Abstract] [Full Text] [Related]

  • 9. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, Tong Y, Liang M, Hu F, Chen HZ.
    Int J Mol Med; 2005 Dec 04; 16(6):1179-84. PubMed ID: 16273304
    [Abstract] [Full Text] [Related]

  • 10. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 04; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 11. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
    Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, Kosai K.
    Cancer Res; 2005 Jun 15; 65(12):5284-91. PubMed ID: 15958575
    [Abstract] [Full Text] [Related]

  • 12. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, Yamamoto M, Wang S, Siegal GP, Curiel DT, McDonald JM.
    Int J Oncol; 2006 Nov 15; 29(5):1319-29. PubMed ID: 17016667
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC, Nie MM, Yang JM, Su CQ, Sun LC, Qian YZ, Sham J, Fang GE, Wu MC, Qian QJ.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):943-8. PubMed ID: 15329284
    [Abstract] [Full Text] [Related]

  • 14. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 2004 Apr 02; 11(4):256-62. PubMed ID: 15017380
    [Abstract] [Full Text] [Related]

  • 15. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.
    Clin Cancer Res; 2006 Nov 01; 12(21):6523-31. PubMed ID: 17085667
    [Abstract] [Full Text] [Related]

  • 16. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I, Cervantes-García D, Martínez-Dávila IA, Ortiz-López R, Alemany-Bonastre R, Silva-Platas CI, Lugo-Trampe A, Barrera-Saldaña HA, Galván-Salazar HR, Coronel-Tene CG, Sánchez-Santillán CF, Rojas-Martínez A.
    J Gene Med; 2007 Oct 01; 9(10):852-61. PubMed ID: 17729237
    [Abstract] [Full Text] [Related]

  • 17. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, Niitsu Y, Nukiwa T.
    Cancer Res; 2004 Jul 01; 64(13):4611-20. PubMed ID: 15231673
    [Abstract] [Full Text] [Related]

  • 18. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J, Choi S, Jung CR, Im DS.
    Mol Ther; 2004 Nov 01; 10(5):938-49. PubMed ID: 15509511
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 01; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 20. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
    Zhu DE, Höti N, Song Z, Jin L, Wu Z, Wu Q, Wu M.
    Cancer Gene Ther; 2006 Aug 01; 13(8):762-70. PubMed ID: 16543917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.